Depression, coupled with substance use, increases vulnerability to adverse life experiences and antisocial and suicidal behaviour in young people. The Epidemiologic Catchment Area studies conducted by the US National Institute of Mental Health in the 1980s found that over half of respondents with a drug-misuse disorder (not including alcohol misuse) also had a psychiatric disorder (most commonly major depression or anxiety). In Australia, about 12% of patients visiting general practitioners have symptoms of depression and substance-misuse problems. Psychiatric disorders may be even more prevalent among patients using methadone and heroin than among other drug users: about 70% of people using heroin in Australia have a psychiatric disorder, compared with 25%–30% of the general population. Depression, anxiety and antisocial personality have been reported to be the most common comorbidities among people using heroin.

Despite the magnitude of the problem, Australian GPs have difficulty identifying and managing both people who misuse drugs and those with mental health disorders. These difficulties are compounded when drug users attend GPs to obtain prescription drugs to augment, supplement or substitute for illegal drugs. "Polydrug" misuse is common in Australia, and prescription drug misuse is a significant problem. GPs write over 15 million prescriptions each year for drugs known to be misused, particularly narcotic analgesics and benzodiazepines — about 8.5% of the total number of prescriptions issued per annum. Requests for opioids, without proper indications for the drug, cause significant discomfort for GPs, but are rarely refused.

Despite being more knowledgeable about benzodiazepines than nicotine or alcohol, GPs report being less confident and less effective when dealing with benzodiazepine use than use of these "non-prescription" drugs. GP confidence is even lower for illicit drugs. Nonetheless, chronic drug addiction brings people using heroin into close contact with GPs and puts GPs in an important position to assess, refer and/or treat drug users.

Our study matched self-report data collected from young people using heroin with Pharmaceutical Benefits Scheme (PBS) prescription drug use as recorded by the Health Insurance Commission. In particular, we tested a model of patterns associated with a history of overdose — personal circumstances (such as age, sex, home stability, family history and employment), mental health (including a history of diagnosed mental illness, and measures of hopelessness, depression, self-harm and antisocial behaviour) and drug use (both illicit and prescription). We sought to identify factors associated with overdose history. These could prove useful for further investigation as risk factors for future overdose.

METHODS

We recruited young people (15–30 years) who used heroin from three inner-metropolitan Melbourne general practices between June and December 2000. A small incentive was offered for participation. Participants were given a copy of the questionnaire, a study description and a guarantee of anonymity. An estimated 30% declined to participate, informally citing lack of benefit of the research or privacy concerns. Questionnaires were self-administered. Consent forms and completed questionnaires were deposited in separate sealed boxes, while signed PBS information release forms were given to their GPs.

Questionnaire

The self-report questionnaire was developed by an advisory committee of GPs, researchers in adolescent health and drug use, psychiatrists, general practitioners and patients with drug and mental health problems.
and mental-health and drug-use counsellors. It comprised questions about personal circumstances, mental health and drug use.

Personal circumstances included categorical and open-ended questions on living arrangements, educational and employment status, and the level of social support from and emotional relationships with family and friends. Responses were aggregated into brief scales indicating levels of social support and quality of emotional relationships.

Scales used to measure mental health included the Beck Hopelessness Scale (BHS),14 which has predicted deliberate non-fatal overdose in adolescents,15 the Short Mood and Feeling Questionnaire (SMFQ),16 for assessing depression; a brief scale measuring self-harm in the past 6 months (BRASH); and antisocial behaviour (for the past 6 months) (Box 1).17 Participants were also asked if they had ever been diagnosed with mental illness (eg, major depression, schizophrenia or psychosis). The questionnaire also measured participants’ duration of heroin use and their patterns of use, and enquired about history of overdose.

PBS data
Completed questionnaires and PBS information release forms were forwarded to the Health Insurance Commission, which provided data on PBS drugs used by each participant over the past 5 years. Data were matched to de-identified questionnaire data. Drugs were grouped into benzodiazepines, other opioids, stimulants, major tranquillisers, antidepressants, anti-infection agents, non-opioid analgesics, and other prescriptions, and counted by frequency of prescription.

Statistical analysis
Data for number of PBS prescriptions, as well as level of perceived social support, dissatisfaction with relationships, self-harm in the past 6 months and hopelessness, were transformed to normal distributions, using appropriate mathematical transformations, to comply with statistical assumptions of normality.

We used logistic regression to determine which factors predicted a history of heroin overdose. The high potential for interrelationship between variables renders simple correlational analyses inappropriate. By entering clusters of variables in clinically meaningful steps in the logistic regression analysis, we were able to control variation due to initial factors before examining variation due to subsequent factors. This tool can reveal significant associations which may be hidden by extraneous variation.

Ethical approval
Ethics approval for this research was granted by the Ethics Committee of the Department of Human Services (Victoria). Anonymity was strictly preserved. Participants could withdraw at any time without prejudice to medical or other treatment, and GPs offered to discuss issues raised by the study with participants.

RESULTS
Participants
Eighteen participants reported not using heroin and were excluded from the study. The remaining 163 who reported having “ever used heroin” (88 men, 74 women and one unspecified) were aged 15–30 years (median, 21 years). When asked if they had ever overdosed (requiring an ambulance or naloxone), 42% agreed (69/163), and 56% disagreed (92/163). Most respondents (64%; 105/161) lived permanently with other people; 30% (49/161) lived alone or in temporary accommodation. Two respondents did not respond to these items. Few participants were employed (23%; 37/163) or studying (12%; 20/163), mostly part-time.

PBS data
PBS data were available for 96 of the participants who, over 5 years (1 August 1996 – 31 July 2001), obtained 6381 prescriptions, averaging 13.5 per person per year (95% CI, 10.6–16.0) — substantially higher than the Australian average of 7.6 per person per year.18 Most prescriptions were for benzodiazepines (56%; 3573/6381), with a further 5% (319/6381) for opioids. There were no differences for any of the variables measured in the study between participants with or without PBS data.

Mental health measures
Guttman’s reliability coefficient lambda was 0.88 for the BHS, 0.95 for the BRASH (indicating high internal consistency), but low (0.62) for the SMFQ. Mean mental health scores (BHS: 5.83 [95% CI, 5.2–6.5]; and SMFQ: 11.75 [95% CI, 10.2–12.8]) were higher than normal population scores. Of the participants, 37.4% (61/163; 95% CI, 18.4%–57.4%) reported self-harm (BRASH) and 85% (138/163; 95% CI, 71.95%–98.05%) reported at least one antisocial incident in the last 6 months. These mental health measures were poorer than in normal populations, but not comparable with those in clinical subpopulations, such as patients with major depression.

Logistic regression analysis
To develop a predictive model discriminating between participants who had overdosed and those who had not, we entered variables for personal circumstances in Step 1 of a logistic regression analysis, mental health variables in Step 2, PBS prescription data in Step 3, and prior mental illness in Step 4 (Box 2). Steps 3 and 4 only used data from the 96 participants for whom PBS data were available. Steps 1 and 2 included all participants.

The variables entered in the first three steps of the model correctly classified 74% of participants (119/161; two participants were excluded from the analysis due to missing data). The last two steps of the analysis resulted in 77% of participants (74/96) being correctly classified. PBS prescription data emerged as the strongest predictor of overdose history, particularly the number of prescriptions for benzodiazepines, antidepressants, opioids and tranquillisers (Box 2). Reanalysis revealed that the effect of antidepressants was due to the influence of tricyclic antidepressants rather than selective serotonin reuptake inhibitors (SSRIs). Tricyclic antidepressants were prescribed for 39/96 (41%) participants (median number [range] of prescriptions, 2 [1–21]), while SSRIs were prescribed for 31/96 (32%) participants (median number [range] of prescriptions, 3 [1–19]). In addition, hopelessness, antisocial

---

**1 Glossary of mental health scales**

BHS: Beck Hopelessness Scale

SMFQ: Short Mood and Feeling Questionnaire

BRASH: Brief Scale of Adolescent Self-Harm (in the past 6 months)

Anti-social behaviour scale

---

**RESULTS**

**Participants**

Eighteen participants reported not using heroin and were excluded from the study. The remaining 163 who reported having “ever used heroin” (88 men, 74 women and one unspecified) were aged 15–30 years (median, 21 years). When asked if they had ever overdosed (requiring an ambulance or naloxone), 42% agreed (69/163), and 56% disagreed (92/163). Most respondents (64%; 105/161) lived permanently with other people; 30% (49/161) lived alone or in temporary accommodation. Two respondents did not respond to these items. Few participants were employed (23%; 37/163) or studying (12%; 20/163), mostly part-time.

**PBS data**

PBS data were available for 96 of the participants who, over 5 years (1 August 1996 – 31 July 2001), obtained 6381 prescriptions, averaging 13.5 per person per year (95% CI, 10.6–16.0) — substantially higher than the Australian average of 7.6 per person per year.18 Most prescriptions were for benzodiazepines (56%; 3573/6381), with a further 5% (319/6381) for opioids. There were no differences for any of the variables measured in the study between participants with or without PBS data.

**Mental health measures**

Guttman’s reliability coefficient lambda was 0.88 for the BHS, 0.95 for the BRASH (indicating high internal consistency), but low (0.62) for the SMFQ. Mean mental health scores (BHS: 5.83 [95% CI, 5.2–6.5]; and SMFQ: 11.75 [95% CI, 10.2–12.8]) were higher than normal population scores. Of the participants, 37.4% (61/163; 95% CI, 18.4%–57.4%) reported self-harm (BRASH) and 85% (138/163; 95% CI, 71.95%–98.05%) reported at least one antisocial incident in the last 6 months. These mental health measures were poorer than in normal populations, but not comparable with those in clinical subpopulations, such as patients with major depression.

**Logistic regression analysis**

To develop a predictive model discriminating between participants who had overdosed and those who had not, we entered variables for personal circumstances in Step 1 of a logistic regression analysis, mental health variables in Step 2, PBS prescription data in Step 3, and prior mental illness in Step 4 (Box 2). Steps 3 and 4 only used data from the 96 participants for whom PBS data were available. Steps 1 and 2 included all participants.

The variables entered in the first three steps of the model correctly classified 74% of participants (119/161; two participants were excluded from the analysis due to missing data). The last two steps of the analysis resulted in 77% of participants (74/96) being correctly classified. PBS prescription data emerged as the strongest predictor of overdose history, particularly the number of prescriptions for benzodiazepines, antidepressants, opioids and tranquillisers (Box 2). Reanalysis revealed that the effect of antidepressants was due to the influence of tricyclic antidepressants rather than selective serotonin reuptake inhibitors (SSRIs). Tricyclic antidepressants were prescribed for 39/96 (41%) participants (median number [range] of prescriptions, 2 [1–21]), while SSRIs were prescribed for 31/96 (32%) participants (median number [range] of prescriptions, 3 [1–19]). In addition, hopelessness, antisocial
behaviour, prior mental illness, young age and dissatisfaction with relationships all predicted overdose history.

Logistic regression analysis was also used to examine the predictors of prior mental illness. Personal circumstances were entered on the first step of this analysis and mental health factors on the second. These factors correctly classified 87% (140/161) of participants. Prior mental illness was associated with being female (Wald’s statistic, 8.56; P<0.001), greater relationship dissatisfaction (Wald’s statistic, 6.43; P<0.01), greater lack of social support (Wald’s statistic, 4.65; P<0.05), self-harm (Wald’s statistic, 4.19; P<0.05), and living alone or in temporary accommodation (Wald’s statistic, 4.96; P<0.01).

**DISCUSSION**

The young people using heroin in our study are a high-risk population. They were highly likely to have had an overdose in the past, they reported misuse of prescription and other drugs, and they may suffer from mental health problems. Self-reported levels of depression, hopelessness, antisocial behaviour and self-harm were considerably higher in our participants than in normative data for the general population. Inclusion of people who declined to participate in our study would only exacerbate this trend, as they seemed to have a less positive attitude towards the benefits of our research than those who participated. In previous studies, prescription drug misuse, poor mental health and chaotic life circumstances (such as unemployment and homelessness) have all been implicated as contributing to heroin overdose risk. Our study attempted to identify which of these factors was most strongly associated.

Somewhat surprisingly, data on PBS prescriptions used (rather than mental health or personal circumstances) emerged as having the strongest association with overdose history, particularly prescriptions for drugs prone to misuse. Large numbers of benzodiazepine, opioid, antidepressant and tranquilliser drugs, all of which may be used to substitute for or enhance the effects of heroin, were associated with overdose history. Although our study excludes victims of fatal overdose (potentially introducing a survivor bias), an associated study of fatal heroin overdose also found a pattern of escalating “doctor shopping” for prescription drugs, particularly for benzodiazepines, opioids and antidepressants.

While opioids and benzodiazepines have a relatively well-known association with both heroin use and overdose risk, the relationship between overdose and antidepressants is less obvious. It is possible that depression is associated with both overdose and the use of antidepressants, and there may not be any direct causal connection between overdose and antidepressants. The effect we found was entirely related to tricyclic antidepressants. These antidepressants are more commonly used by people using heroin; they are cardiotoxic and have contributed to fatal overdose. The association between overdose history and tricyclic antidepressants (but not SSRIs) suggests a causal link between the use or misuse of tricyclic antidepressants and heroin-related overdose. Further investigation of direct causal links between prescription drugs and overdose, however, would require either a detailed analysis of prescription drugs used at the time of overdose, or a prospective study into factors leading to future overdose risk. Such studies would also have the advantage of removing recall errors inherent in self-report studies.

Our study sought to identify which of the factors previously identified as being risk factors for heroin-related overdose (specifically factors related to mental health, personal circumstances and prescription drug use) are most strongly associated with overdose history. There may be other factors (or different mental health scales, for example) not assessed in our study that are also associated with overdose history. Nonetheless, the fact that of all the factors investigated the association with prescription drugs emerged so strongly reinforces the value of using PBS data to examine risk factors associated with heroin use. There were, however, considerable administrative barriers to the use of PBS data in our study, and, for the full clinical benefits of data linkage studies like this one to be realised, more streamlined research procedures need to be put in place. Until such research is undertaken, GPs faced with possible doctor-shoppers can only be supported in their efforts to avoid prescribing drugs known to be misused, not simply because of the economic costs to the PBS, but because of their potential association with overdose and death.

**ACKNOWLEDGEMENTS**

We would like to acknowledge the Australian Divisions of General Practice and beyondblue: the national depression initiative for funding this research. In addition, we would like to thank the Health Insurance Commission, study participants and general practice staff for providing the data. The following individuals also made significant contributions to the study: Dr Yvonne Bonomo; Ms Fleur Champion de Crespigny; Dr Andrew Chanen; Dr Malcolm

---

**SUPPLEMENT • DEPRESSION: REDUCING THE BURDEN**

**Table 2** Logistic regression analysis of the predictive value (Wald’s statistic) of variables measuring personal circumstances, mental health and PBS data for a history of overdosing

<table>
<thead>
<tr>
<th>Variable</th>
<th>Step 1</th>
<th>Step 2</th>
<th>Step 3</th>
<th>Step 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>0.19</td>
<td>0.22</td>
<td>0.70</td>
<td>0.19</td>
</tr>
<tr>
<td>Age</td>
<td>0.29</td>
<td>0.45</td>
<td>2.32</td>
<td>3.25*</td>
</tr>
<tr>
<td>Employment status</td>
<td>0.78</td>
<td>0.69</td>
<td>1.73</td>
<td>1.61</td>
</tr>
<tr>
<td>Relationship dissatisfaction</td>
<td>3.49*</td>
<td>4.11*</td>
<td>3.98*</td>
<td>4.05*</td>
</tr>
<tr>
<td>Perceived social support</td>
<td>1.06</td>
<td>1.17</td>
<td>0.91</td>
<td>1.62</td>
</tr>
<tr>
<td>Living alone/temporary accommodation</td>
<td>3.99*</td>
<td>0.14</td>
<td>0.07</td>
<td>0.01</td>
</tr>
<tr>
<td>Hopelessness (BHS)</td>
<td>4.31*</td>
<td>6.38*</td>
<td>6.12*</td>
<td></td>
</tr>
<tr>
<td>Reported self-harm (BRASH)</td>
<td>0.95</td>
<td>1.74</td>
<td>1.39</td>
<td></td>
</tr>
<tr>
<td>Depression (SMFQ)</td>
<td>0.09</td>
<td>1.43</td>
<td>–1.01</td>
<td></td>
</tr>
<tr>
<td>At least one episode of antisocial behaviour</td>
<td>3.86*</td>
<td>6.52*</td>
<td>8.21*</td>
<td></td>
</tr>
</tbody>
</table>

**Prescriptions**

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Benzosxiazepines</td>
<td>—</td>
<td>—</td>
<td>9.04*</td>
<td>9.25*</td>
</tr>
<tr>
<td>Opioids</td>
<td>—</td>
<td>—</td>
<td>4.09*</td>
<td>3.84*</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>—</td>
<td>—</td>
<td>5.44*</td>
<td>3.99*</td>
</tr>
<tr>
<td>Selective serotonin reuptake inhibitor</td>
<td>—</td>
<td>—</td>
<td>0.98</td>
<td>1.23</td>
</tr>
<tr>
<td>Tricyclic antidepressants</td>
<td>—</td>
<td>—</td>
<td>0.64</td>
<td>4.28*</td>
</tr>
<tr>
<td>Tranquillisers</td>
<td>—</td>
<td>—</td>
<td>4.03*</td>
<td>4.05*</td>
</tr>
<tr>
<td>Prior mental illness</td>
<td>—</td>
<td>—</td>
<td>4.15*</td>
<td></td>
</tr>
</tbody>
</table>

A dash signifies that the variable was not entered on that step of the equation. * P<0.05; † P<0.01; ‡ P<0.001. PBS = Pharmaceutical Benefits Scheme.
See Box 1 for glossary of mental health scales.

---

MJA • Volume 181 Number 7 • 4 October 2004

S27
SUPPLEMENT • DEPRESSION: REDUCING THE BURDEN

Dobbin; Dr David Jacka; Dr John Jagoda; Mr Hal Rosemburg; Ms Lara Watson; Ms Mardie Whitla; and Mr Kim Wyman.

The data used in this report were collected during the “Help Understanding Drug Use (1999–2001) Program” conducted by the Melbourne Division of General Practice, with a grant from the Australian Divisions of General Practice in Canberra. Secondary analysis was funded by beyondblue: the national depression initiative (Melbourne, 2002).

COMPETING INTERESTS
None identified.

REFERENCES

(Received 8 Jan 2004, accepted 6 May 2004)